These symptoms could include mood swings, bloating, or changes in appetite, further indicating the drug's impact on your menstrual cycle
known risks include nausea, raised heart rate, pancreatitis, gallbladder disease, and acute kidney injury from dehydration
GLP1 Wegovy (semaglutide) and GIP Mounjaro (tirzepatide) drugs work on brain receptors that affect appetite, impulses, and the reward system
This mechanism achieved remarkable efficacy in SURMOUNT-1 [1] , where 2,539 participants [1] lost 20.9% body weight at 72 weeks, with 36% achieving 25% or greater weight loss
The approval follows a review of Phase 3 clinical trials conducted in India
The peptide side effects guide covers adverse event profiles in broader context